By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cytokinetics, Inc. 

280 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-624-3000 Fax: 650-624-3010


Drug Discovery

Company News
Cytokinetics (CYTK) Announces First Patient Enrolled In VIGOR-ALS, An Open-Label Extension Clinical Trial Of Tirasemtiv 10/18/2016 7:56:54 AM
Cytokinetics (CYTK) To Announce Third Quarter Results On October 27, 2016 10/17/2016 6:15:24 AM
Cytokinetics (CYTK) Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Expanded Collaboration With Astellas (ALPMY) 9/29/2016 7:43:28 AM
Cytokinetics (CYTK) Announces Presentation Of Additional Results From COSMIC-HF At The HFSA Annual Scientific Meeting 9/19/2016 7:52:13 AM
Cytokinetics (CYTK) Announces Additional Results From COSMIC-HF To Be Presented At The HFSA Annual Scientific Meeting 9/12/2016 7:49:32 AM
Cytokinetics (CYTK) Announces Next-Generation Fast Skeletal Muscle Activator Entering IND-Enabling Studies 9/8/2016 7:58:06 AM
Why Cytokinetics (CYTK) Stock Dropped on the Good News of an Upcoming Phase III Trial 9/2/2016 6:26:17 AM
Cytokinetics (CYTK) And Amgen (AMGN) To Advance Omecamtiv Mecarbil To Phase III Clinical Development 9/1/2016 7:55:08 AM
Cytokinetics (CYTK) Completes Enrollment In VITALITY-ALS, Phase III Clinical Trial Of Tirasemtiv In Patients With ALS 8/17/2016 7:44:02 AM
Comeback Kid Cytokinetics (CYTK) Pockets $95 Million Upfront in R&D Deal With Astellas (ALPMY), Needs Results for More 7/27/2016 8:32:10 AM